The DOI matches its Crossref record; 227 of the 227 references it cites were found in a registry or an index.
Molecular mechanisms of chemo‐ and radiotherapy resistance and the potential implications for cancer treatment
Open accessAbstract
Cancer is a leading cause of death worldwide. Surgery is the primary treatment approach for cancer, but the survival rate is very low due to the rapid progression of the disease and presence of local and distant metastasis at diagnosis. Adjuvant chemotherapy and radiotherapy are important components of the multidisciplinary approaches for cancer treatment. However, resistance to radiotherapy and chemotherapy may result in treatment failure or even cancer recurrence. Radioresistance in cancer is often caused by the repair response to radiation‐induced DNA damage, cell cycle dysregulation, cancer stem cells (CSCs) resilience, and epithelial‐mesenchymal transition (EMT). Understanding the molecular alterations that lead to radioresistance may provide new diagnostic markers and therapeutic targets to improve radiotherapy efficacy. Patients who develop resistance to chemotherapy drugs cannot benefit from the cytotoxicity induced by the prescribed drug and will likely have a poor outcome with these treatments. Chemotherapy often shows a low response rate due to various drug resistance mechanisms. This review focuses on the molecular mechanisms of radioresistance and chemoresistance in cancer and discusses recent developments in therapeutic strategies targeting chemoradiotherapy resistance to improve treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–227 of 227
MDR1 mediated chemoresistance: BMI1 and TIP60 in action
Mustafi, S. B., Chakraborty, P. K., Naz, S., Dwivedi, S. K. D., Street, M., Basak, R., Yang, D., Ding, K., Mukherjee, P., & Bhattacharya, R. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.06.002 · Cited by 32
Cell Cycle Changes after Glioblastoma Stem Cell Irradiation: The Major Role of RAD51
Tachon, G., Cortes, U., Guichet, P., Rivet, P., Balbous, A., Masliantsev, K., Berger, A., Boissonnade, O., Wager, M., & Karayan, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103018 · Cited by 32
Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells
Huang, T., Luo, X., Wu, B., Peng, P., Dai, Y., Hu, G., Qiu, H., & Yuan, X. (2020) · Oncology Reports · doi:10.3892/or.2020.7820 · Cited by 32
DNA repair gets physical: Mapping an XPA-binding site on ERCC1
Croteau, D. L., Ye, P., & Houten, B. V. (2008) · DNA repair · doi:10.1016/j.dnarep.2008.01.018 · Cited by 31
Radiobiological characteristics of cancer stem cells from esophageal cancer cell lines
Wang, J.-L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i48.18296 · Cited by 29
Zhao, Y., Li, Y., LIU, B.-L., He, X., & ZHANG, B.-Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4367 · Cited by 29
Čecháková, L., Ondrej, M., Pavlík, V., Jost, P., Čížková, D., Bezrouk, A., Pejchal, J., Amaravadi, R. K., Winkler, J. D., & Tichý, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235881 · Cited by 29
The centrosome and the DNA damage induced checkpoint
Fletcher, L., & Muschel, R. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.01.006 · Cited by 27
Zhang, Z., Huo, H., Liao, K., Wang, Z., Gong, Z., Li, Y., Liu, C., & Hu, G. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.08.025 · Cited by 27
Treatment of HER2-Positive Metastatic Breast Cancer Following Initial Progression
Mayer, I. A. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.005 · Cited by 26
Chaachouay, H., Fehrenbacher, B., Toulany, M., Schaller, M., Multhoff, G., & Rodemann, H. P. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.08.012 · Cited by 26
Bmi-1 confers adaptive radioresistance to KYSE-150R esophageal carcinoma cells
Wang, G., Liu, L., Sharma, S. P., Liu, H., Yang, W., Sun, X., & Dong, Q. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.087 · Cited by 25
Cieślar‐Pobuda, A., Saenko, Y., & Rzeszowska‐Wolny, J. (2012) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2012.01.005 · Cited by 25
Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells
Conroy, L. R., Lorkiewicz, P., He, L., Yin, X., Zhang, X., Rai, S. N., & Clem, B. F. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01357-x · Cited by 25
Johansson, A., Fleur, L. L., Melissaridou, S., & Roberg, K. B. (2016) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12423 · Cited by 24
Significance of Ras Signaling in Cancer and Strategies for its Control
Gurung, A. B., Bhattacharjee, A., & Researcher (2015) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2015.11.02.147 · Cited by 23
Kikuchi, O., Ohashi, S., Nakai, Y., Nakagawa, S., Matsuoka, K., Kobunai, T., Takechi, T., Amanuma, Y., Yoshioka, M., Ida, T., et al. (2015) · Europe PMC (PubMed Central) · doi:10.14989/doctor.k19597 · Cited by 22
He, H., Chang, R., Zhang, T., Yang, C., & Kong, Z. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6689 · Cited by 20
Chu, C., Niu, X., Ou, X., & Hu, C. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s207810 · Cited by 20
Wang, H., Wang, Y., Xiao, Z., Li, W., Dimitrov, D. S., & Chen, W. (2019) · Antibodies · doi:10.3390/antib8010025 · Cited by 18
Predictors of response and survival for neoadjuvant treated patients with esophageal adenocarcinoma
Theisen, J., Danenberg, K. D., Ott, K., Becker, K., Danenberg, P. V., Stein, H. J., & Siewert, J. R. (2008) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2008.00820.x · Cited by 16
Radio Resistance Mechanisms of Cancers: An Overview and Future Perspectives
Wu, T., Lin, B., & Chang, H. (2015) · Biology and Medicine · doi:10.4172/0974-8369.1000s2-003 · Cited by 16
Zhang, Y., Dong, S., Xu, R., Yang, Y., Zheng, Z., Wang, X., Ren, R., Sun, R., Li, M., Yang, H., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.5780 · Cited by 16
Self-citationGuo, Y., Jia, Y., Wang, S., Liu, N., Gao, D., Zhang, L., Lin, Z., Wang, S., Kong, F., Peng, C., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.7347 · Cited by 12
Self-citationTong, Q., Zhang, W., Jin, S., et al. (2010) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2010.522721 · Cited by 9
Roles of GST-π and polβ Genes in Chemoresistance of Esophageal Carcinoma Cells
Tang, Y., Xuan, X., Li, M., & Dong, Z. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.12.7375 · Cited by 4
(1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(19980701)83:1 · Cited by 3
Cited by
Mitochondrial Metabolism: A New Dimension of Personalized Oncology
Behnam, B., & Taghizadeh-Hesary, F. (2023) · Cancers · doi:10.3390/cancers15164058 · Cited by 44
MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30
Enhancing radiotherapy techniques for Triple-Negative breast cancer treatment
Sarlak, S., Pagès, G., & Luciano, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102939 · Cited by 19
Shiridokht, F., Kehtari, P., Eskandani, M., Farajollahi, A., & Vandghanooni, S. (2025) · International Journal of Pharmaceutics: X · doi:10.1016/j.ijpx.2025.100419 · Cited by 4
Metadata
- Authors
- Liu, Y., Zheng, C., Huang, Y., He, M., Xu, W. W., & Li, B.
- Venue
- MedComm
- Publisher
- Wiley
- Published
- 2021-06-10
- Volume
- 2
- Issue
- 3
- Pages
- 315-340
- ISSN
- 2688-2663 (ISSN-L)
- OpenAlex
- W3172453970
- Cited by
- 387
- References
- 227
- FWCI
- 18.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.